The oral LD50 in rats is >4g/kg.L10824 The intraperitoneal LD50 in mice is 2292mg/kg and in rats is 100mg/kg.L10824
Data regarding acute overdoses of glucocorticoids are rare.L10785,L10788 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.A188405 Treat acute overdoses with symptomatic and supportive therapy, while chronic overdoses will require temporarily reduced dosages.A188405,L10788
Methylprednisolone is a prednisolone derivative glucocorticoid with higher potency than prednisone.A188811 It was first described in the literature in the late 1950s.A188811,A188814
Methylprednisolone was granted FDA approval on 24 October 1957.L10785 In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression.A192813 The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials.L12666
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Methylprednisolone. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Methylprednisolone. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Methylprednisolone. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Methylprednisolone. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Methylprednisolone. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Methylprednisolone. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Methylprednisolone. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Methylprednisolone. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Methylprednisolone. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Methylprednisolone. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Methylprednisolone. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Methylprednisolone. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Methylprednisolone. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Methylprednisolone. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Methylprednisolone. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Methylprednisolone. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Methylprednisolone. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Methylprednisolone. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Methylprednisolone. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Methylprednisolone. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Methylprednisolone. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Methylprednisolone. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Methylprednisolone. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Methylprednisolone. |
| Cladribine | Methylprednisolone may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Methylprednisolone. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Methylprednisolone. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Methylprednisolone. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Methylprednisolone. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Methylprednisolone. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Methylprednisolone. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Methylprednisolone. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Methylprednisolone. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Methylprednisolone. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Methylprednisolone. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Methylprednisolone. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Methylprednisolone. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Methylprednisolone. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Methylprednisolone. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Methylprednisolone. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Methylprednisolone. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Methylprednisolone. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Methylprednisolone. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Methylprednisolone. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Methylprednisolone. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Methylprednisolone. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Methylprednisolone. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Methylprednisolone. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Methylprednisolone. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Methylprednisolone. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Methylprednisolone. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Methylprednisolone. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Methylprednisolone. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Methylprednisolone. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Methylprednisolone. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Methylprednisolone. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Dactinomycin. |
| Azathioprine | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Azathioprine. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Hydroxyurea. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Mycophenolic acid. |
| Topotecan | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Topotecan. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Mercaptopurine. |
| Thalidomide | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Thalidomide. |
| Melphalan | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Melphalan. |
| Fludarabine | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fludarabine. |
| Flucytosine | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Flucytosine. |
| Capecitabine | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Capecitabine. |
| Procarbazine | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Procarbazine. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Arsenic trioxide. |
| Idarubicin | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Idarubicin. |
| Estramustine | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Estramustine. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Mitoxantrone. |
| Lomustine | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Lomustine. |
| Eculizumab | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Eculizumab. |
| Decitabine | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Decitabine. |
| Nelarabine | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Nelarabine. |
| Stepronin | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Stepronin. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Hydroxychloroquine. |
| Castanospermine | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Castanospermine. |
| Vorinostat | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Vorinostat. |
| 2-Methoxyethanol | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with 2-Methoxyethanol. |
| Brequinar | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Brequinar. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pirfenidone. |
| Interferon alfa | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Interferon alfa. |
| Glatiramer | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Glatiramer. |
| Briakinumab | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Briakinumab. |
| Human interferon omega-1 | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Human interferon omega-1. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Mepolizumab. |
| Abetimus | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Abetimus. |
| Belatacept | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Belatacept. |
| Bendamustine | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Bendamustine. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pralatrexate. |
| Wortmannin | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Wortmannin. |
| Eribulin | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Eribulin. |
| Belimumab | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Belimumab. |
| Teriflunomide | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Teriflunomide. |
| Carfilzomib | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Carfilzomib. |
| Dimethyl fumarate | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Dimethyl fumarate. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Obinutuzumab. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Vedolizumab. |